<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201005</url>
  </required_header>
  <id_info>
    <org_study_id>REK-Vest 104.08</org_study_id>
    <nct_id>NCT01201005</nct_id>
  </id_info>
  <brief_title>B Vitamin Status in Premature and Small for Gestational Age(SGA) Infants</brief_title>
  <official_title>B VITAMIN STATUS IN PREMATURE AND SMALL FOR GESTATIONAL AGE INFANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature birth and low birth weight implies insufficient intrauterine growth and fetal
      malnutrition. During the first months of life where the infant is breastfed, the low stores
      aquired during fetal life, may cause specific B vitamin deficiencies. In this study infants
      with a birth weight below 3000 g will be studied at 6 weeks, 4 and 6 months. At 6 months
      infants with biochemical signs of impaired cobalamin status (i.e.: tHcy &gt; 97.5 percentile for
      cobalamin treated infants, i.e.: tHcy&gt;6.5 µM/L) will be randomised to cobalamin treatment or
      placebo. At 7 months the investigators will evaluate the effect of cobalamin or placebo
      treatment according to infant biochemical status and neurodevelopment.

      Study hypothesis: Cobalamin treatment given to infants with biochemical cobalamin deficiency
      will normalize biochemical status and cause improved motor neurodevelopment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in biochemical status and neurodevelopment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bloodsamples for analysis of B vitamin status are drawn before intervention and after 4 weeks Neurological evaluation (AIMS test) of the infants is done before intervention and after 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal evaluation of changes in infant behaviour/development</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maternal evaluation of changes in infant behaviour will be tested by using a maternal questionnaire, Ages and Stages (ASQ), a highly rated child screening and monitoring system, before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Biochemical Cobalamin Status</condition>
  <condition>Motor Neurodevelopment</condition>
  <arm_group>
    <arm_group_label>Hydroxycobalamin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.
The syringe is covered so it is impossible to see whether it contains any substance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>needle injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The controls receive an intramuscular &quot;injection&quot;: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydroxycobalamin</intervention_name>
    <description>Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection</description>
    <arm_group_label>Hydroxycobalamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>needle injection without any substance given</description>
    <arm_group_label>needle injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birthweight &lt; 3000 grams

          -  Age 6 months (+/- 0.5 months)

          -  Plasma total homocysteine &gt; 6.5 umol/L

        Exclusion Criteria:

          -  Plasma total homocysteine &lt; 6.5 umol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Months</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Bjørke-Monsen AL, Torsvik I, Saetran H, Markestad T, Ueland PM. Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. Pediatrics. 2008 Jul;122(1):83-91. doi: 10.1542/peds.2007-2716.</citation>
    <PMID>18595990</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anne-Lise Bjørke Monsen</name_title>
    <organization>Haukeland University Hospital</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

